A Multicenter, Partially-blinded, Randomized, 24-week, Parallel-group, Non-inferiority, Open-label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma

Trial Profile

A Multicenter, Partially-blinded, Randomized, 24-week, Parallel-group, Non-inferiority, Open-label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate; Tiotropium bromide
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ARGON
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2017 Planned number of patients changed from 1500 to 1251.
    • 20 Nov 2017 Planned End Date changed from 17 Apr 2019 to 28 Jun 2019.
    • 20 Nov 2017 Planned initiation date changed from 16 Oct 2017 to 15 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top